Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 17, 2021 / 02:40PM GMT
Release Date Price: $53.35 (-1.75%)
Kevin Michael DeGeeter
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst

All right. I want to thank everyone for joining us today. This is Kevin DeGeeter with Oppenheimer. The next presenting company is Ionis. And it's going to be structured as a fireside chat.

So going to look to just jump right in. Eric, maybe you can just briefly introduce yourself and maybe give us the 60-second overview of the Ionis ASO technology platform? Sure.

Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research

Thanks for having me on, Kevin. I appreciate the opportunity to chat. So I'm Eric Swayze. I am the Head of Research at Ionis. A long time Ionis veteran, I've been here since 1994 and have been heavily involved in bringing the technology forward. So on a medicinal chemist by training and started off trying to make better building blocks for antisense oligonucleotides.

And the 60-second overview is we make precision genetic medicines. They're designed to bind to the -- to all forms -- any form of RNA, which is the intermediary

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot